You just read:

IDEAYA Receives Authorization to Proceed with Phase 1/2 Tissue-Type Agnostic Basket Trial to Treat Patients with Tumors Harboring GNAQ/11 Mutations and PKC Fusions

News provided by

IDEAYA Biosciences, Inc.

May 08, 2019, 06:00 ET